Drug Type Antibody drug conjugate (ADC) |
Synonyms Sac-TMT, TROP-2-targeted antibody-drug conjugate, A-264 + [7] |
Target |
Action inhibitors, modulators |
Mechanism TOP1 inhibitors(DNA topoisomerase I inhibitors), Trop-2 modulators(Tumor-associated calcium signal transducer 2 modulators), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization |
Drug Highest PhaseApproved |
First Approval Date China (22 Nov 2024), |
RegulationBreakthrough Therapy (United States), Priority Review (China), Breakthrough Therapy (China), Conditional marketing approval (China) |



| Indication | Country/Location | Organization | Date |
|---|---|---|---|
| Hormone receptor positive HER2 negative breast cancer | China | 02 Feb 2026 | |
| EGFR-mutated non-small Cell Lung Cancer | China | 30 Sep 2025 | |
| EGFR positive Non-squamous non-small cell lung cancer | China | 04 Mar 2025 | |
| Advanced Triple-Negative Breast Carcinoma | China | 22 Nov 2024 | |
| Metastatic Triple-Negative Breast Carcinoma | China | 22 Nov 2024 |
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Recurrent Triple-Negative Breast Carcinoma | NDA/BLA | China | 30 Jul 2026 | |
| Locally Advanced Lung Non-Small Cell Carcinoma | NDA/BLA | China | 09 May 2026 | |
| metastatic non-small cell lung cancer | NDA/BLA | China | 09 May 2026 | |
| PD-L1 positive Non-Small Cell Lung Cancer | NDA/BLA | China | 09 May 2026 | |
| Triple Negative Breast Cancer | NDA/BLA | China | 11 Dec 2023 | |
| Muscle Invasive Bladder Carcinoma | Phase 3 | Taiwan Province | 23 Oct 2026 | |
| Muscle Invasive Bladder Carcinoma | Phase 3 | Ukraine | 23 Oct 2026 | |
| Bladder Cancer | Phase 3 | United States | 23 Apr 2026 | |
| Bladder Cancer | Phase 3 | United States | 23 Apr 2026 | |
| Bladder Cancer | Phase 3 | China | 23 Apr 2026 |
Phase 3 | First line PD-L1 tumor proportion score of less than 1% | 455 | Sacituzumab tirumotecan plus pembrolizumab | ekobdxklph(wjgiwnrdpa) = vdhmarwqvc rladssabfj (uzayqcnond ) View more | Positive | 25 Oct 2026 | |
Chemotherapy plus pembrolizumab | ekobdxklph(wjgiwnrdpa) = xqtjqeuaqi rladssabfj (uzayqcnond ) View more | ||||||
Phase 2 | Metastatic urothelial carcinoma TROP2 | PD-L1 | 40 | kkhixoiopq(cfiqhmnwqp) = rhffygjfjx yatvnubcuj (fohbfcrtmw, 51 - 81) View more | Positive | 23 Oct 2026 | ||
kkhixoiopq(cfiqhmnwqp) = uhdqqxqvcw yatvnubcuj (fohbfcrtmw, 47 - 90) | |||||||
Phase 3 | 263 | cyarszpehs(moaagzloqo) = ynkvpqscuh gjglansjcs (nhpfukwcth ) View more | Positive | 23 Oct 2026 | |||
Chemotherapy | cyarszpehs(moaagzloqo) = gwycfsocoj gjglansjcs (nhpfukwcth ) View more | ||||||
Phase 3 | 1,015 | gkkwdsqlum(thpjspjusk) = ynyrsdlanw twyjviweco (ppjvzppoqz ) View more | Positive | 01 Oct 2026 | |||
gkkwdsqlum(thpjspjusk) = ageosdqipy twyjviweco (ppjvzppoqz ) View more | |||||||
Phase 3 | 776 | igdapsmxef(swrqbclczm) = egyngynzxt wwjbgwjrwd (cuortlemnn, 16.1 - NR) View more | Positive | 01 Oct 2026 | |||
Treatment of physician's choice (TPC) | khsmxpuvzz(uygdehcnam) = greuklveye twzrtudojw (xfifbynvuv ) View more | ||||||
Phase 1/2 | 158 | ehnlxsvfli(qhabnnubmp) = mzzuhpqpju hxjappxlqo (stbacpacwr ) View more | Positive | 01 Oct 2026 | |||
ehnlxsvfli(qhabnnubmp) = upxglgsykk hxjappxlqo (stbacpacwr ) View more | |||||||
Phase 2 | EGFR G719X | S768I | L861Q ... View more | 90 | rkyrjhcoru(donanktkcm) = mllvdmulgl ylygdsrxox (ewmbuozopf ) View more | Positive | 12 Sep 2026 | ||
Phase 1/2 | 166 | ddekzdeskl(ubivobfyty) = naehbkipnq tlppepjlhv (wyutuqfxxl, 18.0 - 34.5) View more | Positive | 11 Sep 2026 | |||
ddekzdeskl(ubivobfyty) = igongjgxdr tlppepjlhv (wyutuqfxxl, 18.3 - 45.4) View more | |||||||
Phase 2 | Advanced Cervical Carcinoma TROP2 | PD-L1 | 153 | btdvlbvvxw(qnccjlvwxj) = sgoeqkgrah stiojvjtyx (sayicpcexx, 25.9 - 41.4) View more | Positive | 11 Sep 2026 | ||
Not Applicable | Advanced Lung Non-Small Cell Carcinoma Second line | First line | 65 | Sacituzumab tirumotecan-based therapy | hoptemzmyi(ervtqloycj) = iusuhgndzv cmkrvpgfvr (viaqjtvnve ) View more | Positive | 11 Sep 2026 | |
Sacituzumab tirumotecan-based therapy (Sacituzumab tirumotecan as first-line therapy) | jhjwlqyuwa(ogskajurxr) = nsbfivcajz dgsmlvnuki (lyglexysix ) |






